» Articles » PMID: 36698410

Comprehensive Analysis of Mixed Neuroendocrine Non-neuroendocrine Neoplasms (MiNENs): A SEER Database Analysis of 767 Cases

Overview
Journal Front Oncol
Specialty Oncology
Date 2023 Jan 26
PMID 36698410
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN) is an extremely rare entity, consisting of neuroendocrine and non-neuroendocrine components. It can occur in various organs throughout the body, with a rising incidence. Its clinical management is a rapidly growing field of interest; however, large-scale patient cohorts are still missing to guide clinical practice.

Patients And Methods: The demographic, clinicopathological, and survival information of all patients diagnosed with MiNEN in the national Surveillance, Epidemiology, and End Results (SEER) program database (2000-2017) were extracted and further analyzed. The information of the patients before and after 2010 was compared to understand the epidemiological changes of MiNEN. The characteristics of MiNEN originating in different organs were compared. The clinical significance of surgical resection for metastatic MiNENs was also analyzed.

Results: A total of 1081 patients were screened, and after applying the exclusion criteria, 767 patients were finally analyzed. There was no obvious sex preference (49.2% vs 50.8%, p>0.05) and the majority of the patients were Caucasians (n=627, 81.7%). A total of 88.3% of the patients were older than 50 years old, and the median age was 60 years. 79.3% of the tumors are located in the distal digestive tract, and 67.7% were grade 3/4. Distant metastasis was presented in 33.9% of the patients at diagnosis. A total of 88% of the patients underwent surgical treatments. The number of patients increased 10-fold between 2000 and 2017. There was no significant difference in sex, race, stage, or surgical treatments among the patients diagnosed before and after 2010. More patients older than 60 years were diagnosed after 2010 (p=0.009). The median survival was 61.0 ± 9.8 months for the whole cohort. After multivariate analysis, older age (>60 years, p<0.01), more advanced stage (p<0.01), grade 3/4 (p<0.01), and non-surgical treatment (p<0.01) were independent risk factors for poorer survival. The appendiceal MiNENs showed the best prognosis. A total of 260 metastatic MiNENs were further analyzed. Only patients with metastatic MiNENs originating from the appendix had a potential benefit from surgical resection, compared to other sites (p=0.05).

Conclusion: This study provides the epidemiological, clinicopathological, and survival information of the largest number of MiNEN patients. Although MiNEN is an extremely rare malignant neoplasm, its incidence increases rapidly. The majority of the patients suffered from advanced-stage disease, which highlights the need for improvement of early detection in the future. The appendix is the most common primary site of MiNEN, and surgical resection for selected metastatic MiNEN originating in the appendix has favorable survival outcomes.

Citing Articles

Development of a Nomogram-Based Online Calculator for Predicting Cancer-Specific Survival in Patients With Digestive Tract Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms (MiNENs): An Analysis of the SEER Database.

Tang J, Wei S, Tang G, Zhao P Cancer Rep (Hoboken). 2025; 8(2):e70156.

PMID: 39972644 PMC: 11839491. DOI: 10.1002/cnr2.70156.


Survival analysis between different treatment strategies of mixed adenoneuroendocrine carcinoma (MANEC): a population-based study.

Li W, Wang J, Lin J, Sun L, Ouyang M, Ding J Endocr Connect. 2025; 14(3).

PMID: 39907632 PMC: 11850044. DOI: 10.1530/EC-24-0350.


Critical considerations for the management of gastrointestinal mixed neuroendocrine non-neuroendocrine neoplasms and pure neuroendocrine carcinomas.

Pavlidis E, Galanis I, Pavlidis T World J Gastrointest Oncol. 2024; 16(12):4559-4564.

PMID: 39678788 PMC: 11577359. DOI: 10.4251/wjgo.v16.i12.4559.


Gastric mixed neuroendocrine non-neuroendocrine neoplasms.

Liu L, Li Q, Liu W, Qiu Z, Wu Z, Yu D Front Oncol. 2024; 14:1335760.

PMID: 38655135 PMC: 11036886. DOI: 10.3389/fonc.2024.1335760.


Incidence, survival, and prognostic factors for patients with gastrointestinal mixed neuroendocrine non-neuroendocrine neoplasms: a SEER population-based study.

Xu B, Zhang F, Wu R, Peng Y, Mao Z, Tong S J Cancer Res Clin Oncol. 2023; 149(17):15657-15669.

PMID: 37656242 PMC: 10620255. DOI: 10.1007/s00432-023-05356-z.

References
1.
Zhang Z, Zhong D, Feng T, Yao Y, Huang X . Mixed Adenoneuroendocrine Carcinoma of the Gallbladder. J Gastrointest Surg. 2021; 26(2):503-506. DOI: 10.1007/s11605-021-05139-2. View

2.
Raison N, McGovern U, Hines J, Volanis D . Mixed adenoneuroendocrine carcinoma of the urethra. BMJ Case Rep. 2019; 12(3). PMC: 6453422. DOI: 10.1136/bcr-2018-227948. View

3.
Jacob A, Raj R, Allison D, Soares H, Chauhan A . An Update on the Management of Mixed Neuroendocrine-Non-neuroendocrine Neoplasms (MiNEN). Curr Treat Options Oncol. 2022; 23(5):721-735. DOI: 10.1007/s11864-022-00968-y. View

4.
Du X, Song L . Breast cancer incidence trends in Asian women aged 20 or older as compared to other ethnic women in the United States from 2000 to 2018 by time period, age and tumor stage. Cancer Epidemiol. 2021; 76:102076. PMC: 8817625. DOI: 10.1016/j.canep.2021.102076. View

5.
Costa A, Cavalcanti C, Coelho H, Leao L, Soares D, Santa-Cruz F . Rare Mixed Adenoneuroendocrine Carcinoma of the Gallbladder: Case Report and Review of Literature. Am J Case Rep. 2021; 22:e929511. PMC: 8105744. DOI: 10.12659/AJCR.929511. View